These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37259073)

  • 61. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatitis C antibody prevalence and behavioral correlates in people who inject drugs attending harm reduction services in Lisbon, Portugal.
    Curado A; Nogueira PJ; Virgolino A; Santa Maria J; Mendão L; Furtado C; Antunes F
    Front Public Health; 2022; 10():952909. PubMed ID: 36081480
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia.
    Gibbs D; Grebely J; Sutherland R; Larney S; Butler K; Dietze PM; Starr M; Peacock A
    Drug Alcohol Rev; 2021 Nov; 40(7):1349-1353. PubMed ID: 33759276
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
    Djordjevic F; Ryan K; Gunn J; Brener L; O'Keefe D; Draper B; Schroeder S; Gold J; Treloar C; Broady T; Dietze P; Hellard M; Pedrana A
    J Viral Hepat; 2021 Dec; 28(12):1738-1743. PubMed ID: 34510655
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
    Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C
    BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
    Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
    Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.
    Crowley D; Van Hout MC; Lambert JS; Kelly E; Murphy C; Cullen W
    Harm Reduct J; 2018 Dec; 15(1):62. PubMed ID: 30538000
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia.
    Butler K; Day C; Sutherland R; van Buskirk J; Breen C; Burns L; Larney S
    Int J Drug Policy; 2017 Sep; 47():102-106. PubMed ID: 28789820
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.
    Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366561
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Drug use stigma and its association with active hepatitis C virus infection and injection drug use behaviors among community-based people who inject drugs in India.
    Patel EU; Solomon SS; Lucas GM; McFall AM; Tomori C; Srikrishnan AK; Kumar MS; Laeyendecker O; Celentano DD; Thomas DL; Quinn TC; Mehta SH
    Int J Drug Policy; 2021 Oct; 96():103354. PubMed ID: 34247900
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs.
    Midgard H; Bjørnestad R; Egeland M; Dahl E; Finbråten AK; Kielland KB; Blindheim M; Dalgard O
    Liver Int; 2022 Jun; 42(6):1268-1277. PubMed ID: 35362660
    [TBL] [Abstract][Full Text] [Related]  

  • 78. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma.
    Austin EJ; Tsui JI; Barry MP; Tung E; Glick SN; Ninburg M; Williams EC
    J Subst Abuse Treat; 2022 Jun; 137():108684. PubMed ID: 34911656
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Barriers to HIV and Hepatitis C care for people who inject drugs in Colombia.
    Borda JP; Friedman HL; Castaño GA; Rodríguez HA; Muñoz CF; Tofighi B
    AIDS Care; 2022 May; 34(5):633-638. PubMed ID: 33615915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.